MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 3,547 Shares of Vaxcyte, Inc. $PCVX

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 4.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 80,081 shares of the company’s stock after purchasing an additional 3,547 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Vaxcyte worth $3,218,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AlphaQuest LLC acquired a new stake in shares of Vaxcyte during the 1st quarter valued at $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Vaxcyte in the 1st quarter valued at about $35,000. Parallel Advisors LLC increased its position in Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after buying an additional 1,071 shares in the last quarter. IFP Advisors Inc increased its holdings in Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Advisors Asset Management Inc. grew its holdings in shares of Vaxcyte by 81.6% in the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after acquiring an additional 867 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

PCVX stock opened at $32.17 on Friday. The firm has a market capitalization of $4.18 billion, a price-to-earnings ratio of -7.83 and a beta of 1.04. The firm has a 50 day moving average price of $33.16 and a 200-day moving average price of $39.28. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same period last year, the company earned ($1.10) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on PCVX. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday. They issued a “neutral” rating and a $38.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $106.25.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.